Пожалуйста, подождите, мы загружаем данные графика
Novo Nordisk A/S сообщество
About Novo Nordisk A/S
What is Novo Nordisk A/S?
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is 3 011,64 ₽, with a 24-hour trading volume of 12,43B ₽. The asset's market cap is 13,37T ₽, after moving 1.31% in the last day.
Tokenized Novo Nordisk A/S is trading at 3 019,05 ₽, with a tokenized market cap of 245,52M ₽ and a 24-hour trading volume of 65,08M ₽. The tokenized asset has moved 1.98% in the past 24 hours.